Insights & Resources

Is your transaction a business combination or asset acquisition? Learn how ASC 805 guidance, the screen test and key differences shape reporting.

Texas life sciences in 2025 saw concentrated capital, declining innovation output and earlier‑stage clinical shifts shaping the ecosystem.

Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.

Weaver can assist regulated parties with the annual third-party audit requirement under the Environmental Protection Agency’s Hydrofluorocarbon (HFC) phasedown program.

Explore five key provisions in California’s updated LCFS regulation and what they mean for fuel producers, regulated entities and other stakeholders.

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Download our white paper to learn how to even begin to measure and report GHG emissions.

False claims for fuel tax credits land on the IRS’ Dirty Dozen list of tax scams. Learn about the risks and new filing requirements.

Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Weaver has developed carbon accounting processes to determine our carbon footprint across Scope 1 and Scope 2 emissions.